Par announces agreement with GSK to settle Imitrex[R] Injection patent litigation.(Industry News)

Pharmaceutical Processing, December, 2006

Par Pharmaceutical Companies, Inc. recently announced that its partner, Spectrum Pharmaceuticals, Inc., has entered into a settlement agreement with GSK that resolves U.S. patent litigation related to GSK's Imitrex[R] Injection, thereby eliminating the inherent uncertainty and costs of litigation.

The confidential terms of the settlement, which remain subject to government review, permit Par to sell generic versions of certain sumatriptan injection products with an expected launch date during GSK's sumatriptan pediatric exclusivity period which begins on August 6, 2008, but with ...